China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

Eli Lilly and Laekna will collaborate to develop an obesity drug focusing on weight loss while preserving muscle. Lilly aims to solidify its position in the growing $150 billion obesity market by leveraging Laekna's experimental drug, LAE102, which has shown promising results in lab studies.